| Literature DB >> 30806806 |
David J Wellenstein1, Jimmie Honings2, Henrieke W Schutte2, Jasmijn M Herruer2, Frank J A van den Hoogen2, Henri A M Marres2, Robert P Takes2, Guido B van den Broek2.
Abstract
PURPOSE: Although office-based transnasal esophagoscopy has been investigated extensively, a cost analysis is still lacking. We performed a cost analysis combined with feasibility study for two diagnostic processes: patients with globus pharyngeus and/or dysphagia, and hypopharyngeal carcinoma.Entities:
Keywords: Cost analysis; Head and neck oncology; Office-based; Topical anesthesia; Transnasal esophagoscopy
Mesh:
Year: 2019 PMID: 30806806 PMCID: PMC6458968 DOI: 10.1007/s00405-019-05357-0
Source DB: PubMed Journal: Eur Arch Otorhinolaryngol ISSN: 0937-4477 Impact factor: 2.503
Costs for each material per patient category
| Parameter | TNE (€) | Regular diagnostic process for globus pharyngeus and/or dysphagia (€) | Regular diagnostic process for hypopharyngeal carcinoma (€) |
|---|---|---|---|
| Lidocaine | 0.18a | ||
| Attachment for spraying | 0.82a | ||
| Xylometazoline | 1.02a | ||
| Gauze pledgets (10 units) | 0.07a | ||
| Biopsy forceps | 17.00a | ||
| Pathology container | 1.29a | 1.29a | |
| Single wash of endoscope | 24.00a | ||
| Video fluoroscopy | 281.26a | ||
| Consulting pathologist | 114.38a | 114.38a | |
| Surgery (half hour) | 440.00a | ||
| 1-day ward administration | 476.00b | ||
| Outpatient clinic visit | 91.00b | 91.00b | 91.00b |
| Single-use transnasal esophagoscope | 98.87c | ||
| Single-use video processor | 94.68d | 94.68d | 94.68d |
| Single-use transnasal laryngoscope | 85.12e | 85.12e | 85.12e |
aInstitution’s financial department
bDutch Health Institute. Guideline for performance of economic evaluations in healthcare. February 29, 2016 version. https://www.zorginstituutnederland.nl/over-ons/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg (in Dutch). Accessed February 16, 2018
cPentax Medical; €24,718.00/5 (years)/50 (patient’s per year)
dPentax Medical; €23,669.00/5 (years)/50 (patient’s per year)
ePentax Medical; €21.281.00/5 (years)/50 (patient’s per year)
Average number of products used and procedures performed per patient category
| Parameter | TNE (G/D) | TNE (H) | Regular diagnostic process (G/D) | Regular diagnostic process (H) |
|---|---|---|---|---|
| Lidocaine | 1 | 1 | 0 | 0 |
| Attachment for spraying | 1 | 1 | 0 | 0 |
| Xylometazoline | 1 | 1 | 0 | 0 |
| Gauze pledgets (10 units) | 1 | 1 | 0 | 0 |
| Biopsy forceps | 0.35 | 0.73 | 0 | 0 |
| Pathology container | 0.35 | 0.73 | 0 | 1 |
| Single wash of endoscope | 1 | 1 | 0 | 0 |
| Video fluoroscopy | 0 | 0 | 0.8 | 0.07 |
| Consulting pathologist | 0.35 | 0.35 | 0 | 1 |
| Surgery (half hour) | 0 | 0 | 0 | 1 |
| 1-day ward administration | 0 | 0 | 0 | 1 |
| Outpatient clinic visit | 1 | 2 | 2.35 | 2.05 |
| Transnasal esophagoscopy | 1 | 1 | 0 | 0 |
| Transnasal laryngoscopy | 1 | 1 | 1.55 | 1.05 |
G/D globus pharyngeus and/or dysphagia, H hypopharyngeal carcinoma
Patient characteristics
| Characteristics | TNE | % |
|---|---|---|
| Study population | 41 | 100 |
| Sex (males) | 28 | 68.3 |
| Age (range) | 66.6 (29–87) | |
| Indication | ||
| Globus pharyngeus and/or dysphagia | 26 | 63.4 |
| Suspicion hypopharyngeal/esophageal carcinoma | 15 | 36.6 |
| Completed procedures | 35 | 85.3 |
| Discontinued procedures | 6 | 14.7 |
| No nasal passage endoscope | 4 | 9.8 |
| Complication | 2 | 4.9 |
| Duration (range minutes) | 15.03 (6.38–35.00) | |
| Clinical findings | 35 | 100 |
| Globus pharyngeus and/or dysphagia | 20 | 57.1 |
| No suspicious lesions | 11 | 31.4 |
| Laryngeal cyst | 2 | 5.7 |
| Barrett’s esophagusa | 1 | 2.9 |
| Laryngeal carcinoma (primary or residual)a,b | 4 | 11.4 |
| Esophageal carcinomab | 4 | 11.4 |
| Suspected hypopharyngeal tumor | 10 | 28.6 |
| Hypopharyngeal carcinoma | 8 | 22.9 |
| No suspicious lesions | 2 | 5.7 |
| Suspected esophageal tumorc | 5 | 14.3 |
| Esophageal carcinoma | 1 | 2.9 |
| No suspicious lesions | 4 | 11.4 (4/35) |
| Laryngeal carcinomad | 1 | 2.9 |
| Complication | ||
| Epistaxis | 2 | 4.9 |
| Vasovagal reaction | 2 | 4.9 |
| VAS score patient tolerance (average)e | ||
| Burping | 2.2 | |
| Pain in nose | 1.9 | |
| Pain in throat | 1.7 | |
| Gagging | 1.5 | |
| Nausea | 0.3 | |
aOne patient with globus pharyngeus and dysphagia had residual laryngeal carcinoma and Barrett’s esophagus
bOne patient with globus pharyngeus and dysphagia had a tumor in the oral cavity, oropharynx and esophagus
cThese were patients with suspected lesions that were seen on PET and/or CT
dOne patient with a suspected esophageal tumor on PET showed no pathology in the esophagus, but residual laryngeal carcinoma
eVisual analogue scale (VAS): 0 = no complaints, 10 = unbearable complaints